Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival

Annals of Surgery

Volumn 251, Issue 3, 2010, Pages 461-469

  Takahashi, Hidenori ^a   Ohigashi, Hiroaki ^a   Ishikawa, Osamu ^a   Eguchi, Hidetoshi ^a   Gotoh, Kunihito ^a   Yamada, Terumasa ^a   Nakaizumi, Akihiko ^a   Uehara, Hiroyuki ^a   Tomita, Yasuhiko ^a   Nishiyama, Kinji ^a   Yano, Masahiko ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIATION THERAPY; CLASSIFICATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HAZARD RATIO; HUMAN; INDEPENDENT VARIABLE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE PERIOD; PREDICTIVE VALIDITY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SURVIVAL; SURVIVAL RATE; SYSTEMIC DISEASE; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77649159782     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181cc90a3     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol. 2007; 25:3274-3280.
3. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-3502.
4. Golcher H, Brunner T, Grabenbauer G, et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol. 2008;34:756-764.
5. Ohigashi H, Ishikawa O, Eguchi H, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88-95.
6. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preopera-tive chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16: 3843-3850.
7. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20:2537-2544.
8. Quiros RM, Brown KM, Hoffman JP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest. 2007;25:267-273.
9. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13:150-158.
10. Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53-55.
11. Balzano G, Di Carlo V. Is CA 19-9 useful in the management of pancreatic cancer? Lancet Oncol. 2008;9:89-91.
12. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270.
13. Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70:255-264.
14. Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-138.
15. Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897-2902.
16. Nakai Y, Kawabe T, Isayama H, et al. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology. 2008;75:120-126.
17. Heinemann V, Schermuly MM, Stieber P, et al. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res. 1999;19(4A):2433-2435.
18. Ko AH, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195-199.
19. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743.
20. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413-1417.
21. Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg. 1988;208:215-220.
22. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol. 2001;8:123-132.
23. Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248: 1014-1022.
24. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
25. Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-1016.
26. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110:47-55.
27. Lawrence TS, Chang EY, Hahn TM, et al. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'- deoxycytidine (Gemcitabine). Clin Cancer Res. 1997;3:777-782.
28. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. IntJRadiat Oncol Biol Phys. 1996;34:867-872.
29. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363: 1049-1057.
30. Park JK, Ryu JK, Lee JK, et al. Gemcitabine chemotherapy versus 5-fluorou-racil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas. 2006;33:397-402.
31. Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918-5922.
32. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32:35-41.
33. Smith RA, Bosonnet L, Ghaneh P, et al. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma. Dig Surg. 2008;25:226-232.
34. Zhang S, Wang YM, Sun CD, et al. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol. 2008;14:3750-3753.
35. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorode-oxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-929.
36. Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol. 2008;15: 2465-2471.
37. Mayo SC, Austin DF, Sheppard BC, et al. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg. 2009;208:87-95.
38. Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg. 2001;88:325-337.
39. Rose DM, Delbeke D, Beauchamp RD, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999;229:729-737; discussion 737-738.
40. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164-169.